Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | TOP1 | P11387 | 2/20 | 0.38 |
| ▸ | ACACA | Q13085 | 4/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10030807 | 0.86 | ADORA1 (0.40) | MEN1KMT2AALDH1A1HPGDADORA2A | |
| SCHEMBL10001009 | 0.86 | MEN1 (0.32) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL10000975 | 0.86 | MEN1 (0.45) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL19009619 | 0.86 | TOP1 (0.43) | MEN1KMT2AALDH1A1MAPTADORA2A | |
| SCHEMBL595855 | 0.86 | ADORA2A (0.45) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL347336 | 0.83 | ADORA1 (0.42) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL10000984 | 0.83 | MEN1 (0.43) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL23434685 | 0.83 | MEN1 (0.58) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL10001008 | 0.82 | MEN1 (0.42) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL346750 | 0.82 | ADORA1 (0.41) | MEN1KMT2AALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8475686-B2 | Bridged pyridoquinazoline or phenanthroline compounds and organic semiconducting material comprising that compound | NOVALED AG (DE) | 2013-07-02 | — | — | US | disclosed |
| US-8475686-B2 | Bridged pyridoquinazoline or phenanthroline compounds and organic semiconducting material comprising that compound | NOVALED AG (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20120012794-A1 | Bridged Pyridoquinazoline or Phenanthroline Compounds and Organic Semiconducting Material Comprising That Compound | NOVALED AG (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120012794-A1 | Bridged Pyridoquinazoline or Phenanthroline Compounds and Organic Semiconducting Material Comprising That Compound | NOVALED AG (DE) | 2012-01-19 | — | — | US | disclosed |
| EP-2194055-A1 | Bridged pyridoquinazoline or phenanthroline compounds and organic semiconducting material comprising that compound | Novaled AG (DE) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120012794-A1 | Bridged Pyridoquinazoline or Phenanthroline Compounds and Organic Semiconducting Material Comprising That Compound | PNPO, SDHB, PAH | MEN1 243/4885KMT2A 838/4885ALDH1A1 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.